Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Rheumatoid Arthritis AND Arthritis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44359   clinical trials with a EudraCT protocol, of which   7382   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    852 result(s) found for: Rheumatoid Arthritis AND Arthritis. Displaying page 11 of 43.
    EudraCT Number: 2007-000828-40 Sponsor Protocol Number: C87076 Start Date*: 2008-02-26
    Sponsor Name:UCB Pharma S.A.
    Full Title: A Phase IIIB, multi-centre, double-blind randomized, placebo-controlled, parallel group 52-week study to evaluate safety and efficacy of the PEGylated anti-TNFα Fab′fragment, certolizumab pegol, ad...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) AT (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-004000-35 Sponsor Protocol Number: DRI13926 Start Date*: 2017-02-24
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 1 to 17 Years, with Systemic Juvenil...
    Medical condition: Juvenile Idiopathic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) EE (Prematurely Ended) FI (Trial now transitioned) CZ (Completed) PL (Completed) NL (Ongoing) Outside EU/EEA BG (Trial now transitioned) IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-011206-42 Sponsor Protocol Number: INCB 28050-201 Start Date*: 2009-08-18
    Sponsor Name:Incyte Corporation
    Full Title: A Randomized, Double Blind, Placebo Controlled, Dose Ranging, Parallel Group, Phase 2 Study of INCB028050 Compared to Background Therapy in Patients with Active Rheumatoid Arthritis with Inadequate...
    Medical condition: Active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2012-004631-22 Sponsor Protocol Number: TapERA2012 Start Date*: 2013-01-15
    Sponsor Name:University Hospitals Leuven
    Full Title: TapERA: Maintaining remission in RA while tapering Etanercept.
    Medical condition: reumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002339-27 Sponsor Protocol Number: I4V-MC-JADX Start Date*: 2013-01-14
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Inadequate Response to Conventional Disease-Modifying A...
    Medical condition: Moderately to severely active rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) DE (Completed) IT (Completed) PT (Completed) GB (Completed) CZ (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-019935-37 Sponsor Protocol Number: ML25346 Start Date*: 2010-09-15
    Sponsor Name:Roche Oy
    Full Title: A pragmatic, randomized, parallel group study of the effect on disease remission, work productivity, and tolerability of tocilizumab in combination with DMARDs and individually designed best practi...
    Medical condition: Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039073 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2010-019438-28 Sponsor Protocol Number: 2010-019438-28 Start Date*: 2010-05-17
    Sponsor Name:Mälarsjukhuset Eskilstuna
    Full Title: Vaccination against TBE in patients who use immunosuppressive drugs
    Medical condition: TBE vaccin in patients using immunosuppressive drugs
    Disease: Version SOC Term Classification Code Term Level
    12.1 10046859 Vaccination LLT
    12.1 10037153 Psoriasis LLT
    12.1 10039073 Rheumatoid arthritis LLT
    12.1 10054980 Immunosuppressant drug therapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005096-12 Sponsor Protocol Number: OPRERA Start Date*: 2021-05-31
    Sponsor Name:Karolinska Universitetssjukhuset
    Full Title: Utvärdering av två kortison behandlingsstrategier hos patienter med nydiagnostiserad, tidigare obehandlad reumatoid artrit: en randomiserad, öppen, non-inferiority klinisk studie
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-001105-42 Sponsor Protocol Number: H9B-MC-BCDG Start Date*: 2008-09-16
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2 Study of Multiple Intravenous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFα Inhibit...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) AT (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-023692-26 Sponsor Protocol Number: D4300C00004 Start Date*: 2011-04-07
    Sponsor Name:AstraZeneca AB
    Full Title: (OSKIRA-4): A Phase IIB, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium Monotherapy Compared with Adalimumab M...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-005759-41 Sponsor Protocol Number: WA20496 Start Date*: 2008-03-19
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the safety and Efficacy of Ocrelizumab Given as a Single Infusion or Dual Infusion Compared with Placebo in Patients with...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) DE (Prematurely Ended) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-011000-34 Sponsor Protocol Number: CAIN457F2201 Start Date*: 2009-09-30
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 16-week multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-finding study to evaluate the efficacy, safety and tolerability of subcutaneous AIN457 followed by an exten...
    Medical condition: Moderate to severe Rheumatoid Arthritis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed) BE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2005-002629-30 Sponsor Protocol Number: CDP870-051 Start Date*: 2006-01-30
    Sponsor Name:UCB Inc
    Full Title: A Phase III Multi-center, Open-label, Follow-up Study, to Assess the Safety and Efficacy of Liquid Certolizumab Pegol as Additional Medication to Methotrexate, in the Treatment of Signs and Symptom...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    10039073
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) SK (Completed) CZ (Completed) EE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2008-005427-28 Sponsor Protocol Number: C87094 Start Date*: 2009-04-22
    Sponsor Name:UCB Pharma SA
    Full Title: A Phase IIIb, multicenter study with a 12-week double-blind, placebo-controlled, randomized period followed by an open-label, extension phase to evaluate the safety and efficacy of certolizumab peg...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) ES (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-007185-33 Sponsor Protocol Number: 3242K1-2000-WW Start Date*: 2010-01-12
    Sponsor Name:Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company
    Full Title: A Seamless, Phase 1/2, Multiple Ascending Dose, Proof of Concept Study of ATN-103 Administered to Subjects With Active Rheumatoid Arthritis on a Background of Methotrexate
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) BE (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022243-38 Sponsor Protocol Number: CNTO136ARA3003 Start Date*: 2012-07-11
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) DE (Completed) GB (Completed) AT (Completed) ES (Completed) PT (Completed) BE (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2004-002846-36 Sponsor Protocol Number: A3921019 Start Date*: 2005-06-14
    Sponsor Name:Pfizer Pharma GmbH
    Full Title: A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO COMPARE 3 DOSE LEVELS OF CP 690,550 VERSUS PLACEBO, ADMINISTERED ORALLY TWICE DAILY (BID) FOR 6 WEEKS, IN THE TREATME...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    7.1 10039073 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) SK (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-000609-58 Sponsor Protocol Number: NN8226-3612 Start Date*: 2013-02-20
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoi...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Prematurely Ended) GB (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021449-28 Sponsor Protocol Number: PHRI10 – DM – AFORA Start Date*: 2010-10-04
    Sponsor Name:CHRU de TOURS
    Full Title: Valeur prédictive de la concentration sérique d’Adalimumab (Humira) sur la réponse clinique dans la polyarthrite rhumatoïde
    Medical condition: Polyarthrite rhumatoïde
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004398-16 Sponsor Protocol Number: W10-046 Start Date*: 2008-10-08
    Sponsor Name:Abbott Scandinavia AB
    Full Title: A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable RA Patients in Clinical remission
    Medical condition: Adalimumab has the indication for life-long treatment of RA but can adalimumab be discontinued in patients who are in stable clinical remission (DAS28<2.6) with retained low disease activity or wil...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Oct 15 21:09:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA